SDZNY vs. STVN: Which Stock Is the Better Value Option?

Zacks Equity Research identifies Sandoz Group AG Sponsored ADR (SDZNY) as a superior value option compared to Stevanato Group (STVN) within the Medical-Drugs sector. SDZNY holds a Zacks Rank of #2 (Buy) and a Value Style Score of B, indicating an improving earnings outlook and favorable valuation metrics. In contrast, STVN has a Zacks Rank of #3 (Hold) and a Value Style Score of C, with significantly higher forward P/E (43.25 vs. 20.24), PEG (2.46 vs. 1.12), and P/B (4.76 vs. 3.29) ratios, positioning SDZNY as the more attractive investment for value-oriented investors.

Analysis

Zacks Equity Research identifies Sandoz Group AG (SDZNY) as a superior value option compared to Stevanato Group (STVN) within the Medical-Drugs sector. This assessment is underpinned by SDZNY's Zacks Rank of #2 (Buy) and a Value Style Score of B, contrasting with STVN's Zacks Rank of #3 (Hold) and a Value Style Score of C. SDZNY's higher Zacks Rank is specifically attributed to positive earnings estimate revision trends, signaling an improving fundamental outlook.

Valuation metrics further reinforce SDZNY's favorable position for value investors. SDZNY currently trades at a forward P/E ratio of 20.24, significantly lower than STVN's 43.25. Its PEG ratio of 1.12 also presents a more attractive valuation when factoring in expected earnings growth, compared to STVN's 2.46.

Additionally, SDZNY's P/B ratio stands at 3.29, which is notably below STVN's 4.76. These combined metrics contribute to SDZNY's stronger Value Grade and suggest a relative undervaluation compared to STVN, positioning it as a more compelling choice for value-oriented portfolios. The overall sentiment for SDZNY is highly positive (0.8), while STVN receives a less favorable sentiment score (-0.3) in this comparative analysis.

Key Decisions for Investors

• Investors seeking value opportunities in the Medical-Drugs sector should consider Sandoz Group AG (SDZNY) given its Zacks Rank #2 (Buy) and superior valuation metrics compared to Stevanato Group (STVN).
• Focus on SDZNY's positive earnings estimate revision trends as a key indicator of its improving fundamental outlook and potential for continued value appreciation.
• Monitor the comparative P/E, PEG, and P/B ratios to continuously assess SDZNY's relative undervaluation against peers and its sustained attractiveness for value-focused strategies.